BSc, PhD, Clinical Product Lead, NPS MedicineWise, NSW.
BPharm (Hons), GradPharmMed, MHM, Cardiovascular Risk Reduction Manager, Heart Foundation Australia, NSW.
Aust J Gen Pract. 2021 Apr;50(4):238-245. doi: 10.31128/AJGP-02-20-5222.
Approximately 65% of cardiovascular disease (CVD)-related deaths in Australia occur in people with diabetes or pre-diabetes. The aim of this study was to investigate general practice management of risk factors among patients with both conditions.
This was a cross-sectional study of 33,559 adult patients with both type 2 diabetes and CVD at 1 November 2018, using the general practice data program MedicineInsight.
One-third of patients did not have a record in their current medications list for all three recommended medicines to reduce cardiovascular risk. Potentially suboptimal monitoring and achievement of targets for diabetes and cardiovascular risk factors was also identified. Most patients using metformin-based combination therapy were prescribed blood glucose-lowering medicines that do not have evidence of cardiovascular benefit.
These data suggest opportunities to support general practices to optimise patient management. Datasets such as MedicineInsight can help practices identify patients who may benefit from recall.
在澳大利亚，约 65%的心血管疾病（CVD）相关死亡发生在糖尿病或糖尿病前期患者中。本研究旨在调查这两种疾病患者的全科医疗管理风险因素的情况。
这是一项针对 2018 年 11 月 1 日患有 2 型糖尿病和 CVD 的 33559 名成年患者的横断面研究，使用全科医疗数据计划 MedicineInsight。
三分之一的患者在其当前药物清单中没有记录所有三种推荐的降低心血管风险的药物。还发现对糖尿病和心血管风险因素的监测和达标情况并不理想。大多数使用基于二甲双胍的联合治疗的患者被开了没有心血管获益证据的降血糖药物。
这些数据表明，有机会支持全科医生优化患者管理。像 MedicineInsight 这样的数据集可以帮助医生确定可能受益于召回的患者。
